Perlmutter Cancer Center

This is a multicenter, open-label, Phase 1 study which will be conducted in 2 parts: a dose-escalation part and a dose expansion part. Patients with advanced melanoma, renal cell carcinoma, non-small cell lung cancer (NSCLC), bladder cancer, ovarian cancer, and triple negative breast cancer will be considered for this study. In the dose-escalation part of the study, patients will receive ALKS 4230, an investigational drug by intravenous (IV) administration daily for 5 days, followed by 16 days off, for a total of 21 days (3 weeks) for each cycle. For the first 2 treatment cycles, subjects will receive ALKS 4230 as inpatients at a medical facility with immediate access to the intensive care unit (ICU) and medical support measures.